ENYO Pharma is a clinical stage company with an innovative approach inspired by viruses. Our biotech mimics virus strategy to modulate host cellular functions with multiple applications.
We develop new drug candidates in multiple indications such as infectious diseases (e.g. HBV), metabolic diseases (e.g. NASH) and oncology.
Our main candidate Vonafexor (EYP001, FXR agonist) is in Phase 2 for both chronic hepatitis B and Non-Alcoholic Steato-Hepatitis. Our second candidate, EYP002, is currently in preclinical studies. Initially developed against influenza virus, it has a mitochondrial cellular target which leads ENYO Pharma to explore new indications such as oncology or metabolic diseases.
Thanks to the MIMESIS project, funded by European Union’s Horizon 2020 Research and Innovation Program, ENYO Pharma has a portfolio of early molecules for various indications (RSV, Immunogenic Cell Death, Zika virus, rhinovirus, influenza virus and Mycobacterium tuberculosis)
ENYO Pharma is also a member of the CARE consortium (Corona Accelerated R&D in Europe), the largest European research initiative addressing the drug discovery challenges of COVID-19, funded by IMI 2 JU.
ENYO Pharma is currently based in Lyon, France and in Melbourne, Australia.
We develop new drug candidates in multiple indications such as infectious diseases (e.g. HBV), metabolic diseases (e.g. NASH) and oncology.
Our main candidate Vonafexor (EYP001, FXR agonist) is in Phase 2 for both chronic hepatitis B and Non-Alcoholic Steato-Hepatitis. Our second candidate, EYP002, is currently in preclinical studies. Initially developed against influenza virus, it has a mitochondrial cellular target which leads ENYO Pharma to explore new indications such as oncology or metabolic diseases.
Thanks to the MIMESIS project, funded by European Union’s Horizon 2020 Research and Innovation Program, ENYO Pharma has a portfolio of early molecules for various indications (RSV, Immunogenic Cell Death, Zika virus, rhinovirus, influenza virus and Mycobacterium tuberculosis)
ENYO Pharma is also a member of the CARE consortium (Corona Accelerated R&D in Europe), the largest European research initiative addressing the drug discovery challenges of COVID-19, funded by IMI 2 JU.
ENYO Pharma is currently based in Lyon, France and in Melbourne, Australia.
Location: France, Auvergne-Rhône-Alpes, Lyon
Employees: 11-50
Total raised: $71.19M
Founded date: 2014
Investors 3
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
| - | Andera Par... | anderapart... |
| - | OrbiMed | orbimed.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.06.2018 | Series B | $46.8M | - |
| 03.02.2016 | Series A | $24.39M | - |
Mentions in press and media 7
| Date | Title | Description |
| 02.05.2023 | Startup Showcase: ENYO Pharma – Fighting Viruses with Intracellular Targets | Enigmatic biopharmaceutical startup ENYO Pharma is at the forefront of the fight against viruses. Based in the Infectiology Center of Lyonbiopôle in Lyon, France, the company has developed a unique platform for the identification of intrace... |
| 04.06.2018 | Term Sheet — Wednesday, June 4 | BRAIN DRAIN Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop Andreessen Horowitz poured $100 million in the startup back in 2012, making it the largest single check the firm had ever wr... |
| 04.06.2018 | ENYO Pharma raises €40 million in Series B fundraising | |
| 04.06.2018 | Enyo Pharma Raises €40M in Series B Funding | Enyo Pharma, a Lyon, France-based clinical stage biotech company developing innovative drug candidates by mimicking virus strategies to modulate host cellular functions, completed a €40m in Series B financing. The round was led by OrbiMed, ... |
| 03.02.2016 | Enyo Pharma Secures €22M Series A Financing | Enyo Pharma, a Lyon, France-based biopharmaceutical company focused on developing treatments for acute and chronic viral infections, secured a €22m Series A financing round. The round was led by Sofinnova Partners, with participation from M... |
| 03.02.2016 | UPDATED: Enyo Pharma gets a $24M funding boost for hep B cure candidate | By Ben Adams The new French biotech Enyo Pharma has raised a good chunk of money in its first round of financing as it looks to start human testing for a potential hepatitis B cure. The company, which was founded in 2014, raised €22 million... |
| - | ENYO Pharma | “ENYO Pharma – Developing therapeutics for diseases with impaired kidney function” |